Mastorino Luca, Dapavo Paolo, Avallone Gianluca, Merli Martina, Cariti Caterina, Rubatto Marco, Pala Valentina, Quaglino Pietro, Ribero Simone
Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
J Dermatolog Treat. 2022 Aug;33(5):2495-2502. doi: 10.1080/09546634.2021.1970706. Epub 2021 Aug 30.
Available evidence to guide clinicians in the management of psoriasis patients with a history of malignancies is scarce. The latest generation of biological drugs is traditionally considered to be safe in patients with previous malignancy, although only case reports and short case series on the use of biological drugs in this population are available in the literature. In this paper, we present the experience of our clinic on 37 psoriatic patients with a previous diagnosis of neoplasia treated subsequently with biological drugs. Subsequently, a systematic review of the literature was performed and 38 cases were found. The main biologic used in our patients and the patients described in the literature was secukinumab. In both populations treatment with biologics was safe, disease progressions reported were not related to treatment. Based on our experience, which is the largest currently available, and the cases reported in the literature the treatment of psoriasis in patients with previously diagnosed cancer with biologics against TNFalpha, IL17, IL23, and IL12 would appear to be safe. The first experience on the use of Risankizumab and brodalumab on this special population is also reported in our series.
指导有恶性肿瘤病史的银屑病患者管理的现有证据很少。传统上认为最新一代生物药物对既往有恶性肿瘤的患者是安全的，尽管文献中仅有关于该人群使用生物药物的病例报告和简短病例系列。在本文中，我们介绍了我们诊所对37例先前诊断为肿瘤、随后接受生物药物治疗的银屑病患者的经验。随后，我们对文献进行了系统回顾，发现了38例病例。我们的患者以及文献中描述的患者使用的主要生物制剂是司库奇尤单抗。在这两个人群中，生物制剂治疗都是安全的，报告的疾病进展与治疗无关。基于我们目前最大规模的经验以及文献中报道的病例，对于先前诊断为癌症的患者，使用抗TNFα、IL17、IL23和IL12的生物制剂治疗银屑病似乎是安全的。我们的系列研究中还报告了在这一特殊人群中使用瑞莎珠单抗和布罗达单抗的首次经验。
